Skip to main content

Dare We Say Consensus Achieved: Lecanemab Slows the Disease

UCI MIND Director Joshua Grill, PhD is featured in and comments on Alzforum’s report on “convincing and noteworthy” lecanemab results.

The slightly larger effect on [activities of daily living] ADLs caught the interest of some scientists, since these can feel most important to participants. “[This] indicates that patients and families could benefit from slowing of observable functional worsening,” Joshua Grill of the University of California, Irvine, wrote to Alzforum (full comments below).

Read his commentary here >

Read the full article here >

Diverging Trajectories. People on lecanemab worsened more slowly on the CDR-SB than did people on placebo, resulting in a quarter less progression at 18 months. [Courtesy of Eisai.]